NASDAQ:MYOS

MYOS RENS Technology (MYOS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$1.01
$11.40
52-Week Range
N/A
Volume
N/A
Average Volume
1.68 million shs
Market Capitalization
$16.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About MYOS RENS Technology

MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.

MYOS Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Bio-active Peptides Market Size Dynamics 2023-2029
Exposed: 10 CENT Crypto to Explode April 20th?
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
See More Headlines
Receive MYOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOS RENS Technology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2019
Today
4/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MYOS
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Net Income
$-4,260,000.00
Net Margins
-277.82%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.03 million
Book Value
$0.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$16.70 million
Optionable
Not Optionable
Beta
1.08
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Ed Kilroy
    President, Chief Executive Officer & Director
  • Ryan Ferguson
    Chief Financial Officer, Secretary & Treasurer
  • Fraser Mackay
    Chief Information Officer
  • David John Rawlins
    Chief Commercial Officer
  • Neil Prezioso
    Chief Pharmacy Officer

MYOS Stock Analysis - Frequently Asked Questions

How were MYOS RENS Technology's earnings last quarter?

MYOS RENS Technology Inc. (NASDAQ:MYOS) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The business had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.14 million. MYOS RENS Technology had a negative trailing twelve-month return on equity of 166.68% and a negative net margin of 277.82%.

What other stocks do shareholders of MYOS RENS Technology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MYOS RENS Technology investors own include Chesapeake Energy (CHKAQ), Catalyst Pharmaceuticals (CPRX), Biocept (BIOC), Global Blood Therapeutics (GBT), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX) and BioLineRx (BLRX).

This page (NASDAQ:MYOS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners